Stocks Health care IMA

NASDAQ · Health care

ImageneBio, Inc. (IMA)

It posted a net loss of $52.5M. At June 30, 2026 it held $94.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.

Watch IMA in 60 seconds

Follow IMA

Free, no password. An email when IMA files with the SEC.

Key facts about ImageneBio, Inc.

Net worth

ImageneBio, Inc. has a market value (market cap) of $45.1M at the latest share price, and shareholders' equity of $142.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Revenue and profit

In fiscal 2025 revenue was $800K (-77.1% year on year), with a net loss of $45.3M.

Cash flow

In fiscal 2025 operations used $47.8M of cash.

Latest report

The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 5, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR

Next earnings report

ImageneBio, Inc.'s next report was expected around November 3, 2026 and is not on file with the SEC yet.

What ImageneBio, Inc. does

ImageneBio, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker IMA.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Where IMA ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What ImageneBio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 14, 2026
   Passive stake changed SCHEDULE 13G/A
2. August 5, 2026
   Employee stock plan registration S-8
3. August 5, 2026
   Shelf registration to sell securities S-3
4. August 5, 2026
   Form POS AM filing POS AM
5. August 5, 2026
   Shelf registration to sell securities S-3
6. August 5, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.63 versus -$4.46.
7. August 5, 2026
   Quarterly results 8-K
8. July 23, 2026
   Executive or director change 8-K
9. June 26, 2026
   Executive or director change 8-K
10. June 17, 2026
    Executive or director change 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 17, 2026. Insider transactions on SEC

Insider trades

What the people running ImageneBio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 3 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns IMA

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Deep Track Capital, LP 0% (February 13, 2026); Atlas Venture Fund X, L.P. 2.1% (July 29, 2025); Leonard Braden Michael 1.9% (July 28, 2025).

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 35 managers reported a position.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

5 insiders reported holding 694,838 shares in total, about $2.8M at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about IMA

What does ImageneBio, Inc. do?

ImageneBio, Inc. is a company in the Health care sector, listed on NASDAQ as IMA. Its shares trade on NASDAQ under the ticker IMA.

What is ImageneBio, Inc.'s net worth?

ImageneBio, Inc. has a market value (market cap) of $45.1M at the latest share price, and shareholders' equity of $142.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is ImageneBio, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $52.5M.

When did ImageneBio, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 17, 2026.

When is ImageneBio, Inc.'s next earnings report?

ImageneBio, Inc.'s next report was expected around November 3, 2026 and is not on file with the SEC yet.

Similar companies

Compare IMA with

Compare IMA with any company

Follow IMA

Get an email when ImageneBio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow IMA

Free, no password. An email when IMA files with the SEC.

Where the numbers come from

Financial figures are the values ImageneBio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.